Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent

Study identifier:NIS-OKR-CAS-2010/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent

Medical condition

GnRH agonist alone vs. GnRH agonist plus anti-androgen combination treated prostate cancer patients

Phase

-

Healthy volunteers

No

Study drug

-

Sex

Male

Actual Enrollment

312

Study type

Observational

Age

50 Years +

Date

Study Start Date: 01 Apr 2011
Primary Completion Date: 01 Feb 2014
Study Completion Date: 01 Feb 2014

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2015 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria